Renovaro Historical Balance Sheet

RENB Stock

0.34 0.03 9.68%

Trend analysis of Renovaro Biosciences balance sheet accounts such as Other Stockholder Equity of 551.6 M, Total Liab of 37.6 M, Common Stock of 18.7 K or Total Assets of 197 M provides information on Renovaro Biosciences' total assets, liabilities, and equity, which is the actual value of Renovaro Biosciences to its prevalent stockholders. By breaking down trends over time using Renovaro Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Renovaro Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Renovaro Biosciences is a good buy for the upcoming year.

Renovaro Biosciences Inventory

(375,617)

Build AI portfolio with Renovaro Stock

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renovaro Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.

About Renovaro Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Renovaro Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Renovaro Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Renovaro Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Renovaro currently owns. An asset can also be divided into two categories, current and non-current.

Renovaro Biosciences Balance Sheet Chart

At present, Renovaro Biosciences' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 36.6 M, whereas Total Stockholder Equity is forecasted to decline to about 78.5 M.

Other Current Liab Total Current Liabilities Common Stock Total Equity Total Liab Capital Lease Obligations

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Renovaro Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Renovaro Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Capital Lease Obligations

Renovaro Biosciences capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Renovaro Biosciences asset purchases. For example, Renovaro Biosciences can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Renovaro Biosciences control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.

Most accounts from Renovaro Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Renovaro Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renovaro Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.At present, Renovaro Biosciences' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 36.6 M, whereas Total Stockholder Equity is forecasted to decline to about 78.5 M.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	11.0M	30.3M	34.9M	36.6M
Other Current Liabilities	723.2K	17.9M	20.6M	21.6M

Total Current Liabilities Other Current Liab

Renovaro Biosciences balance sheet Correlations

	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Common Stock Total Equity	Other Stockholder Equity	Total Liab	Common Stock	Total Assets	Short Long Term Debt Total	Net Debt	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Current Assets	Short Term Debt	Non Current Assets Total	Non Currrent Assets Other	Intangible Assets	Net Tangible Assets	Accounts Payable	Other Assets	Retained Earnings Total Equity	Capital Surpluse
Other Current Liab		0.98	0.33	-0.84	0.62	0.85	0.87	0.96	0.54	0.09	0.44	-0.32	-0.32	0.76	0.91	-0.25	-0.22	0.65	0.44	-0.2	-0.31	-0.58	0.96	-0.22	-0.49	0.4
Total Current Liabilities	0.98		0.3	-0.89	0.66	0.87	0.88	0.97	0.52	0.11	0.49	-0.36	-0.36	0.83	0.93	-0.28	-0.25	0.77	0.42	-0.22	-0.33	-0.66	0.99	-0.22	-0.54	0.43
Total Stockholder Equity	0.33	0.3		-0.41	0.79	0.67	0.64	0.52	0.95	0.87	-0.49	0.66	0.66	0.14	0.57	0.64	0.72	0.11	0.99	0.49	0.77	-0.08	0.25	0.38	-0.76	0.88
Retained Earnings	-0.84	-0.89	-0.41		-0.82	-0.92	-0.83	-0.91	-0.56	-0.38	-0.42	0.16	0.16	-0.91	-0.94	0.16	0.06	-0.86	-0.51	0.2	0.13	0.64	-0.88	0.16	0.78	-0.68
Common Stock Total Equity	0.62	0.66	0.79	-0.82		0.94	0.82	0.8	0.88	0.8	-0.06	0.35	0.35	0.65	0.88	0.29	0.44	0.62	0.83	0.14	0.43	-0.37	0.62	0.17	-0.96	0.92
Other Stockholder Equity	0.85	0.87	0.67	-0.92	0.94		0.94	0.96	0.83	0.57	0.15	0.09	0.09	0.77	0.98	0.1	0.19	0.71	0.75	0.03	0.15	-0.53	0.84	0.01	-0.86	0.79
Total Liab	0.87	0.88	0.64	-0.83	0.82	0.94		0.94	0.81	0.47	0.09	0.07	0.07	0.7	0.92	0.22	0.17	0.62	0.73	0.09	0.1	-0.65	0.85	0.02	-0.69	0.67
Common Stock	0.96	0.97	0.52	-0.91	0.8	0.96	0.94		0.71	0.33	0.32	-0.14	-0.14	0.79	0.98	-0.09	-0.03	0.72	0.62	-0.09	-0.09	-0.59	0.95	-0.11	-0.7	0.61
Total Assets	0.54	0.52	0.95	-0.56	0.88	0.83	0.81	0.71		0.81	-0.35	0.53	0.53	0.33	0.74	0.55	0.61	0.28	0.96	0.41	0.62	-0.23	0.47	0.3	-0.8	0.85
Short Long Term Debt Total	0.09	0.11	0.87	-0.38	0.8	0.57	0.47	0.33	0.81		-0.52	0.76	0.76	0.18	0.44	0.7	0.79	0.2	0.84	0.49	0.85	-0.06	0.07	0.54	-0.81	0.9
Net Debt	0.44	0.49	-0.49	-0.42	-0.06	0.15	0.09	0.32	-0.35	-0.52		-0.9	-0.9	0.53	0.3	-0.82	-0.88	0.54	-0.39	-0.75	-0.8	-0.46	0.54	-0.47	0.02	-0.22
Cash	-0.32	-0.36	0.66	0.16	0.35	0.09	0.07	-0.14	0.53	0.76	-0.9		1.0	-0.35	-0.07	0.86	0.98	-0.33	0.57	0.54	0.9	0.41	-0.42	0.48	-0.37	0.49
Cash And Short Term Investments	-0.32	-0.36	0.66	0.16	0.35	0.09	0.07	-0.14	0.53	0.76	-0.9	1.0		-0.35	-0.07	0.86	0.98	-0.33	0.57	0.54	0.9	0.41	-0.42	0.48	-0.37	0.49
Net Receivables	0.76	0.83	0.14	-0.91	0.65	0.77	0.7	0.79	0.33	0.18	0.53	-0.35	-0.35		0.8	-0.28	-0.25	0.84	0.25	-0.26	-0.32	-0.7	0.84	-0.21	-0.59	0.46
Common Stock Shares Outstanding	0.91	0.93	0.57	-0.94	0.88	0.98	0.92	0.98	0.74	0.44	0.3	-0.07	-0.07	0.8		-0.06	0.04	0.74	0.66	-0.11	0.0	-0.55	0.9	-0.08	-0.8	0.7
Non Current Liabilities Total	-0.25	-0.28	0.64	0.16	0.29	0.1	0.22	-0.09	0.55	0.7	-0.82	0.86	0.86	-0.28	-0.06		0.85	-0.31	0.58	0.62	0.84	0.03	-0.32	0.54	-0.26	0.44
Total Current Assets	-0.22	-0.25	0.72	0.06	0.44	0.19	0.17	-0.03	0.61	0.79	-0.88	0.98	0.98	-0.25	0.04	0.85		-0.25	0.64	0.53	0.89	0.34	-0.32	0.47	-0.45	0.56
Short Term Debt	0.65	0.77	0.11	-0.86	0.62	0.71	0.62	0.72	0.28	0.2	0.54	-0.33	-0.33	0.84	0.74	-0.31	-0.25		0.21	-0.29	-0.29	-0.67	0.8	-0.06	-0.58	0.45
Non Current Assets Total	0.44	0.42	0.99	-0.51	0.83	0.75	0.73	0.62	0.96	0.84	-0.39	0.57	0.57	0.25	0.66	0.58	0.64	0.21		0.44	0.68	-0.19	0.37	0.34	-0.78	0.9
Non Currrent Assets Other	-0.2	-0.22	0.49	0.2	0.14	0.03	0.09	-0.09	0.41	0.49	-0.75	0.54	0.54	-0.26	-0.11	0.62	0.53	-0.29	0.44		0.63	0.04	-0.22	0.53	-0.04	0.29
Intangible Assets	-0.31	-0.33	0.77	0.13	0.43	0.15	0.1	-0.09	0.62	0.85	-0.8	0.9	0.9	-0.32	0.0	0.84	0.89	-0.29	0.68	0.63		0.3	-0.36	0.55	-0.47	0.61
Net Tangible Assets	-0.58	-0.66	-0.08	0.64	-0.37	-0.53	-0.65	-0.59	-0.23	-0.06	-0.46	0.41	0.41	-0.7	-0.55	0.03	0.34	-0.67	-0.19	0.04	0.3		-0.71	0.1	0.27	-0.28
Accounts Payable	0.96	0.99	0.25	-0.88	0.62	0.84	0.85	0.95	0.47	0.07	0.54	-0.42	-0.42	0.84	0.9	-0.32	-0.32	0.8	0.37	-0.22	-0.36	-0.71		-0.29	-0.51	0.4
Other Assets	-0.22	-0.22	0.38	0.16	0.17	0.01	0.02	-0.11	0.3	0.54	-0.47	0.48	0.48	-0.21	-0.08	0.54	0.47	-0.06	0.34	0.53	0.55	0.1	-0.29		-0.18	0.27
Retained Earnings Total Equity	-0.49	-0.54	-0.76	0.78	-0.96	-0.86	-0.69	-0.7	-0.8	-0.81	0.02	-0.37	-0.37	-0.59	-0.8	-0.26	-0.45	-0.58	-0.78	-0.04	-0.47	0.27	-0.51	-0.18		-0.93
Capital Surpluse	0.4	0.43	0.88	-0.68	0.92	0.79	0.67	0.61	0.85	0.9	-0.22	0.49	0.49	0.46	0.7	0.44	0.56	0.45	0.9	0.29	0.61	-0.28	0.4	0.27	-0.93

Click cells to compare fundamentals

Renovaro Biosciences Account Relationship Matchups

Renovaro Biosciences balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Other Current Liab	1.3M	3.6M	723.2K	17.9M	20.6M	21.6M
Total Current Liabilities	1.9M	6.5M	11.0M	30.3M	34.9M	36.6M
Total Stockholder Equity	174.7M	72.6M	46.5M	132.0M	151.8M	78.5M
Retained Earnings	(90.9M)	(204.3M)	(244.0M)	(324.7M)	(292.2M)	(277.6M)
Other Stockholder Equity	265.6M	277.0M	290.6M	456.8M	525.3M	551.6M
Total Liab	14.9M	12.0M	11.8M	31.2M	35.8M	37.6M
Common Stock	5.2K	5.3K	6.4K	15.5K	17.8K	18.7K
Total Assets	189.6M	84.6M	58.3M	163.1M	187.6M	197.0M
Short Long Term Debt Total	7.3M	7.0M	5.6M	3.8M	4.4M	3.4M
Net Debt	(13.4M)	(2.2M)	3.7M	3.6M	3.2M	3.4M
Cash	20.7M	9.2M	1.9M	220.5K	253.5K	240.9K
Cash And Short Term Investments	20.7M	9.2M	1.9M	220.5K	253.5K	240.9K
Net Receivables	20.8K	2.0K	1.6K	1.1M	1.3M	1.3M
Common Stock Shares Outstanding	47.2M	52.5M	56.3M	96.2M	110.7M	116.2M
Liabilities And Stockholders Equity	189.6M	84.6M	58.3M	163.1M	187.6M	197.0M
Non Current Liabilities Total	13.1M	5.6M	775.6K	842.4K	968.7K	920.3K
Total Current Assets	20.9M	9.6M	2.6M	2.0M	2.3M	2.2M
Short Term Debt	292.4K	1.5M	5.0M	2.9M	3.4M	3.6M
Non Current Assets Total	168.7M	75.1M	55.7M	161.1M	185.3M	96.5M
Non Currrent Assets Other	21.0K	68.6K	21.7K	19.8K	17.9K	17.0K
Accumulated Other Comprehensive Income	(10.8K)	(30.4K)	(29.9K)	(170.8K)	(153.8K)	(146.1K)
Intangible Assets	154.9M	61.6M	42.7M	30.0K	34.5K	32.8K
Net Tangible Assets	(269.1K)	8.1M	(636.4K)	(7.8M)	(7.0M)	(6.7M)
Accounts Payable	320.6K	1.4M	5.3M	9.4M	10.9M	11.4M
Other Current Assets	232.9K	393.0K	690.9K	668.9K	602.0K	363.0K
Capital Lease Obligations	1.5M	1.2M	969.0K	1.3M	1.5M	945.9K
Net Invested Capital	180.4M	78.4M	51.1M	134.4M	154.6M	130.5M
Property Plant And Equipment Gross	2.2M	2.1M	1.9M	2.3M	2.7M	1.6M
Net Working Capital	19.0M	3.1M	(8.5M)	(28.3M)	(25.5M)	(24.2M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

AMT	American Tower Corp
HLTOY	Hellenic Telecommunications Org
NFLX	Netflix

When determining whether Renovaro Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Renovaro Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Renovaro Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Renovaro Biosciences Stock:

How To Invest In Renovaro

Details

Is Renovaro Stock a good investment?

Details

What is Renovaro Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Renovaro Biosciences. If investors know Renovaro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Renovaro Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.95)

Return On Assets

(0.18)

Return On Equity

(1.88)

The market value of Renovaro Biosciences is measured differently than its book value, which is the value of Renovaro that is recorded on the company's balance sheet. Investors also form their own opinion of Renovaro Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Renovaro Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renovaro Biosciences' market value can be influenced by many factors that don't directly affect Renovaro Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Renovaro Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Renovaro Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renovaro Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Renovaro Historical Balance Sheet

Renovaro Biosciences Inventory

(375,617)

About Renovaro Balance Sheet Analysis

Renovaro Biosciences Balance Sheet Chart

Total Current Liabilities

Common Stock Total Equity

Total Liab

Capital Lease Obligations

Renovaro Biosciences balance sheet Correlations

Renovaro Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Renovaro Biosciences balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Accounts Payable	+ 0.99	Total Current Liabilities
Non Current Assets Total	+ 0.99	Total Stockholder Equity
Total Current Liabilities	+ 0.98	Other Current Liab
Common Stock Shares Outstanding	+ 0.98	Other Stockholder Equity
Common Stock Shares Outstanding	+ 0.98	Common Stock

Retained Earnings Total Equity	- 0.96	Common Stock Total Equity
Common Stock Shares Outstanding	- 0.94	Retained Earnings
Capital Surpluse	- 0.93	Retained Earnings Total Equity
Other Stockholder Equity	- 0.92	Retained Earnings
Net Receivables	- 0.91	Retained Earnings
Common Stock	- 0.91	Retained Earnings